A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. Approach and Results: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was −0.5 (95% CI, −0.7 to −0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. Conclusions: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 1×
“[15,16] 17 – 19] Aldafermin exhibits biased FGFR4-KLB receptor signaling through modification within the amino terminus to eliminate tumorigenicity while retaining potent activity to suppress CYP7A1, which encodes the first and rate-limiting enzyme of bile acid synthesis.”
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029349 · Cited by 1,146 · cited 2×
“[2] This is a vexing issue in pivotal trial design where the selection of patients with disease that may still be responsive to therapeutic intervention needs to be balanced with the regulatory requirement to show a positive impact on clinical outcomes, which would require a very large long-term…”
Self-citationLoomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
Self-citationHarrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.027 · Cited by 497 · cited 2×
“…(delta) was seen with aldafermin 3 mg compared with NASH cirrhosis trials (delta of 8% for aldafermin, 3% for obeticholic acid, 1% for selonsertib, [7] − 2% for belapectin, [8] − 3% for pegbelfermin, [10] and − 18% for semaglutide [11] ; negative delta indicating worse fibrosis response in the…”
InfluentialSelf-citationSanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S., Shiffman, M. L., Aguilar Schall, R., Jia, C., McColgan, B., et al. (2019) · Hepatology · doi:10.1002/hep.30664 · Cited by 390 · cited 1×
“[13,27] In the current ALPINE-4 trial, aldafermin 3 mg achieved a treatment difference of − 0.5 as compared to placebo in patients with NASH and compensated cirrhosis, which compares favorably to improvements in ELF noted in NASH cirrhosis trials (eg, − 0.3 for semaglutide, [11] − 0.2 for…”
InfluentialSelf-citationHarrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384
Self-citationChalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358
Self-citationHarrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280
Self-citation
Research works printed but not linked: 18
- Noureddin, 2018, NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances, Am J Gastroenterol, 113, 1649, 10.1038/s41395-018-0088-6 · DOI · Paper page
- Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 · DOI · Paper page
- Huang, 2023, Global epidemiology of cirrhosis - aetiology, trends and predictions, Nat Rev Gastroenterol Hepatol, 20, 388, 10.1038/s41575-023-00759-2 · DOI · Paper page
- Garcia-Tsao, 2020, Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension, J Hepatol, 72, 885, 10.1016/j.jhep.2019.12.010 · DOI · Paper page
- Abdelmalek, 2023, Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study, Clin Gastroenterol Hepatol, S1542-3565(23)00311-7
- Davison, 2020, Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials, J Hepatol, 73, 1322, 10.1016/j.jhep.2020.06.025 · DOI · Paper page
- DePaoli, 2019, FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis, Diabetes, 68, 1315, 10.2337/db18-1305 · DOI · Paper page
- Smirnova, 2022, Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD, Hepatology, 76, 1811, 10.1002/hep.32568 · DOI
- Sanyal, 2021, Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases, JHEP Rep, 3, 100255, 10.1016/j.jhepr.2021.100255 · DOI · Paper page
- Harrison, 2018, NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 391, 1174, 10.1016/S0140-6736(18)30474-4 · DOI · Paper page
- Harrison, 2022, Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Gastroenterol Hepatol, 7, 603, 10.1016/S2468-1253(22)00017-6 · DOI · Paper page
- Noureddin, 2020, Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum, Gastroenterology, 159, 422, 10.1053/j.gastro.2020.04.039 · DOI
- Are, 2021, Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis, Clin Gastroenterol Hepatol, 19, 1292, 10.1016/j.cgh.2020.06.070 · DOI
- Trembling, 2020, The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease, BMC Gastroenterol, 20, 104, 10.1186/s12876-020-01251-w · DOI
- Nielsen, 2013, The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters, Am J Transl Res, 5, 303
- Nielsen, 2023, PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease, JHEP Rep, 5, 100743, 10.1016/j.jhepr.2023.100743 · DOI
- Rinella, 2019, Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis, J Hepatol, 70, 735, 10.1016/j.jhep.2018.11.032 · DOI · Paper page
- Anania, 2021, Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration, Hepatology, 73, 2023, 10.1002/hep.31687 · DOI · Paper page
Cited by
Liver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
Lifestyle interventions in nonalcoholic fatty liver disease
Younossi, Z. M., Zelber-Sagi, S., Henry, L., & Gerber, L. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00800-4 · Cited by 281
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis
Ursic-Bedoya, J., Desandré, G., Chavey, C., Marie, P., Polizzi, A., Rivière, B., Guillou, H., Assenat, E., Hibner, U., & Gregoire, D. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00021-x · Cited by 11
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
Metadata
- Authors
- Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W.-S., Younes, Z. H., Sheikh, A. M., Brannan, D., Freilich, B., Membreno, F., Sinclair, M., Melchor-Khan, L., Sanyal, A. J., Ling, L., & Harrison, S. A.
- Venue
- Hepatology
- Published
- 2023-09-21
- Volume
- 79
- Issue
- 3
- Pages
- 674-689
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4386910070
- Cited by
- 94
- References
- 13
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. https://app.cochat.ai/papers/10.1097/hep.0000000000000607
- The paper
- Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W.-S., Younes, Z. H., Sheikh, A. M., Brannan, D., Freilich, B., Membreno, F., Sinclair, M., Melchor-Khan, L., Sanyal, A. J., Ling, L., & Harrison, S. A. (2024). A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. https://doi.org/10.1097/hep.0000000000000607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.